Last reviewed · How we verify

Michael C Roarke, MD — Portfolio Competitive Intelligence Brief

Michael C Roarke, MD pipeline: 0 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amsterdam UMC, location VUmc · 1 shared drug class
  2. Blue Earth Diagnostics · 1 shared drug class
  3. Brigham and Women's Hospital · 1 shared drug class
  4. Genzyme, a Sanofi Company · 1 shared drug class
  5. Gustave Roussy, Cancer Campus, Grand Paris · 1 shared drug class
  6. HTA Co., Ltd. · 1 shared drug class
  7. IRCCS San Raffaele · 1 shared drug class
  8. ITEL Telecomunicazioni Srl · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Michael C Roarke, MD:

Cite this brief

Drug Landscape (2026). Michael C Roarke, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/michael-c-roarke-md. Accessed 2026-05-16.

Related